Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 5/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | GGH | Q92820 | 1/20 | 0.33 |
| ▸ | CCKBR | P32239 | 1/20 | 0.31 |
| ▸ | FAP | Q12884 | 1/20 | 0.30 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.30 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.30 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.30 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4965556 | 0.92 | DPP4 (0.44) | DPP4LMNA | |
| SCHEMBL4965687 | 0.90 | DPP4 (0.46) | DPP4LMNA | |
| SCHEMBL4964998 | 0.88 | DPP4 (0.47) | DPP4LMNA | |
| SCHEMBL4965749 | 0.87 | DPP4 (0.43) | DPP4 | |
| SCHEMBL4968314 | 0.87 | DPP4 (0.43) | DPP4LMNAFAP | |
| SCHEMBL4965052 | 0.87 | DPP4 (0.46) | DPP4LMNA | |
| SCHEMBL4965419 | 0.86 | DPP4 (0.46) | DPP4LMNA | |
| SCHEMBL4968320 | 0.86 | DPP4 (0.46) | DPP4LMNA | |
| SCHEMBL4967555 | 0.85 | DPP4 (0.41) | DPP4LMNA | |
| SCHEMBL4964334 | 0.84 | L3MBTL1 (0.45) | DPP4ACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1489088-B1 | NOVEL ALPHA-AMINO-N-(DIAMINOPHOSPHINYL)LACTAM DERIVATIVE | NIPPON KAYAKU KK (JP) | 2008-08-13 | — | — | EP | disclosed |
| US-7348318-B2 | α-Amino-N-(diaminophosphinyl)lactam derivatives | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2008-03-25 | — | — | US | disclosed |
| US-20050164989-A1 | Novel $g(a)-amino-n-(diaminophosphinyl) lactam derivative | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2005-07-28 | — | — | US | disclosed |
| EP-1489088-A1 | NOVEL ALPHA-AMINO-N-(DIAMINOPHOSPHINYL)LACTAM DERIVATIVE | Nippon Kayaku Kabushiki Kaisha (JP) | 2004-12-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050164989-A1 | Novel $g(a)-amino-n-(diaminophosphinyl) lactam derivative | DNPEP, PEPD, ANPEP | DPP4 8/4885LMNA 2427/4885GGH 28/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.